Participant flow

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib · Source last updated 2017-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.

   id

   FG000

   title

   TKI258

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         16

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         49

      type

      Disease Progression

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Subject/guardian decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         80

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         80

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice